Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
John Gordon FreundDirector | Collegium PharmaceuticalCOLL | Open-market sale | 05/18 | 05/20 | 20 sh | $34.05 | $681 | −0.0% |
John Gordon FreundDirector | Collegium PharmaceuticalCOLL | Open-market sale | 05/15 | 05/18 | 4,127 sh | $34.54 | $142,546.58 | −4.7% |
Nancy LurkerDirector | Collegium PharmaceuticalCOLL | Open-market sale | 05/13 | 05/15 | 4,500 sh | $35.97 | $161,865 | −20.0% |
Garen G. BohlinDirector | Collegium PharmaceuticalCOLL | Open-market sale | 05/11 | 05/13 | 8,700 sh | $37.18 | $323,466 | −12.3% |
David DieterEVP & General Counsel | Collegium PharmaceuticalCOLL | Open-market sale10b5-1 plan | 03/18 | 03/20 | 13,976 sh | $34.92 | $488,041.92 | −15.4% |
David DieterEVP & General Counsel | Collegium PharmaceuticalCOLL | Open-market sale10b5-1 plan | 03/09 | 03/11 | 6,224 sh | $36.65 | $228,109.6 | −6.4% |
Collegium PharmaceuticalCOLL | Open-market sale10b5-1 plan | 03/03 | 03/05 | 49,976 sh2 trades | $40.40avg. | $2,019,273.53 | −41.0% | |
Collegium PharmaceuticalCOLL | Open-market sale10b5-1 plan | 25/12/08 | 25/12/10 | 17,600 sh2 trades | $48.17avg. | $847,849.75 | −14.5% | |
Rita J. Balice-GordonDirector | Collegium PharmaceuticalCOLL | Open-market sale | 25/12/05 | 25/12/09 | 3,650 sh | $47.03 | $171,659.5 | −6.5% |
John A. FallonDirector | Collegium PharmaceuticalCOLL | Open-market sale | 25/11/12 | 25/11/14 | 34,853 sh | $47.21 | $1,645,410.13 | −35.0% |
Collegium PharmaceuticalCOLL | Open-market sale10b5-1 plan | 25/11/06 | 25/11/07 | 30,000 sh2 trades | $40.53avg. | $1,215,772.2 | −19.1% | |
Thomas B. SmithEVP and Chief Medical Officer | Collegium PharmaceuticalCOLL | Open-market sale | 25/08/29 | 25/09/03 | 17,478 sh | $38.42 | $671,504.76 | −19.9% |
Scott DreyerEVP & Chief Commercial Officer | Collegium PharmaceuticalCOLL | Open-market sale10b5-1 plan | 25/08/18 | 25/08/20 | 16,389 sh | $38.21 | $626,223.69 | −13.7% |
Gino SantiniDirector | Collegium PharmaceuticalCOLL | Open-market sale | 25/08/15 | 25/08/19 | 5,405 sh | $37.19 | $201,011.95 | −5.4% |
Rubric Capital Management10% Owner | Collegium PharmaceuticalCOLL | Open-market sale | 25/08/13 | 25/08/15 | 25,000 sh | $37.85 | $946,250 | −0.8% |
Scott DreyerEVP & Chief Commercial Officer | Collegium PharmaceuticalCOLL | Open-market sale10b5-1 plan | 25/08/13 | 25/08/15 | 4,861 sh | $38.03 | $184,863.83 | −4.5% |
John Gordon FreundDirector | Collegium PharmaceuticalCOLL | Open-market sale | 25/08/08 | 25/08/12 | 11,659 sh | $34.36 | $400,603.24 | −33.5% |
John Gordon FreundDirector | Collegium PharmaceuticalCOLL | Open-market sale | 25/06/09 | 25/06/11 | 6,601 sh | $30.62 | $202,122.62 | −8.5% |
Collegium PharmaceuticalCOLL | Open-market sale10b5-1 plan | 25/03/20–25/03/21 | 25/03/24 | 20,808 sh2 trades | $30.03avg. | $624,806.43 | −16.7% | |
Collegium PharmaceuticalCOLL | Open-market sale10b5-1 plan | 25/03/20–25/03/21 | 25/03/24 | 7,602 sh2 trades | $30.03avg. | $228,251.88 | −4.6% |